Pyxis Oncology, Inc.
PYXS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PYXS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PYXS
Pyxis Oncology, Inc. is a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) targeting solid tumors, with its lead candidate micvotabart pelidotin (formerly PYX-201) in Phase 1/2 trials. The company has no approved products, has not generated product revenue, and has incurred significant operating losses since inception.
Key risk: No approved products or revenue
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 3 clinical trials for Pyxis Oncology, Inc..
Pyxis Oncology, Inc. is a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) targeting solid tumors, with its lead candidate micvotabart pelidotin (formerly PYX-201) in Phase 1/2 trials. The company has no approved products, has not generated product revenue, and has incurred significant operating losses since inception.
- Pyxis Oncology has no products approved for sale and has not generated any revenue from product sales [sec_mda · as of 2026-05-14].
- As of June 30, 2026, the company reported cash and equivalents of $20.3 million, net income of -$25.3 million, and shareholders' equity of $87.6 million [sec].
- The company reported an accumulated deficit of $466.4 million as of March 31, 2026 [sec_mda · as of 2026-05-14].
- Pyxis Oncology is advancing its lead product candidate, micvotabart pelidotin (formerly PYX-201), in clinical trials for solid tumors [sec_mda · as of 2025-11-03].
- The company has a shelf registration statement on Form S-3 filed in November 2025 for up to $350.0 million in securities, and had $150.0 million remaining capacity under an ATM facility as of March 31, 2026 [sec_mda · as of 2026-05-14].
What works
- Pyxis Oncology has a lead ADC candidate, micvotabart pelidotin, in clinical development for solid tumors, with potential for monotherapy and combination therapy [sec_mda · as of 2025-11-03].
- The company has access to additional capital through a $350.0 million shelf registration and an ATM facility with $150.0 million remaining capacity as of March 31, 2026 [sec_mda · as of 2026-05-14].
- Pyxis Oncology is conducting clinical trials in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), with preliminary data anticipated in the second half of 2025 [sec_mda · as of 2025-08-14].
What to weigh
- Pyxis Oncology has no approved products and has not generated any product revenue, relying entirely on financing to fund operations [sec_mda · as of 2026-05-14].
- The company has incurred significant operating losses, with net losses of $23.3 million for the three months ended March 31, 2026, and an accumulated deficit of $466.4 million as of that date [sec_mda · as of 2026-05-14].
- Cash and equivalents were only $20.3 million as of June 30, 2026, which may limit the company's ability to fund ongoing and future clinical trials without additional financing [sec].
- The company expects expenses to increase substantially as it advances clinical trials for micvotabart pelidotin, increasing the need for future capital [sec_mda · as of 2026-05-14].
From the filings
Quoted directly from source documents.
The company has no approved products and no product revenue.
“We do not have any products approved for sale and have not generated any revenue from product sales.”
SEC MD&A · May 14, 2026
The company reported an accumulated deficit of $466.4 million as of March 31, 2026.
“As of March 31, 2026, we had an accumulated deficit of $466.4 million”
SEC MD&A · May 14, 2026
The company had cash, cash equivalents and marketable debt securities of $41.0 million as of March 31, 2026.
“We had cash, cash equivalents and marketable debt securities of $41.0 million as of March 31, 2026.”
SEC MD&A · May 14, 2026
The company filed a registration statement for up to $350.0 million in securities.
“On November 26, 2025, we filed a registration statement on Form S-3 with the SEC for the issuance of common stock, preferred stock, warrants, debt securities, rights and units with an aggregate offering price of up to $350.0 million.”
SEC MD&A · May 14, 2026
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Pyxis has no products approved for sale and has not generated any product revenue, relying entirely on financing [sec_mda · as of 2026-05-14].
- Significant operating losses — Net loss of $23.3 million for Q1 2026 and accumulated deficit of $466.4 million as of March 31, 2026 [sec_mda · as of 2026-05-14].
- Limited cash runway — Cash and equivalents of only $20.3 million as of June 30, 2026, which may not sustain operations without additional financing [sec].
- Clinical development risks — The company's lead candidate micvotabart pelidotin is still in clinical trials, with no guarantee of success or regulatory approval [sec_mda · as of 2026-05-14].
What to watch
- Preliminary clinical data from the micvotabart pelidotin trial in R/M HNSCC, anticipated in the second half of 2025 [sec_mda · as of 2025-08-14].
- The company's ability to secure additional financing given its limited cash position of $20.3 million as of June 30, 2026 [sec].
- Updates on the advancement of micvotabart pelidotin into combination therapy trials and any regulatory milestones [sec_mda · as of 2026-05-14].
- Progress on the ATM facility and shelf registration to raise capital for ongoing operations [sec_mda · as of 2026-05-14].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Pyxis Oncology, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Pyxis Oncology, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
5.7 months
D/E 3.80 · 0% dilution
Lead: Phase 1/Phase 2
4 candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
74
Total value held
$27.6M
| Holder | Shares | Value |
|---|---|---|
| laurion capital management lp | 4,997,333 | $7.3M |
| vanguard capital management llc | 4,067,020 | $5.9M |
| atle fund management ab | 197,036 | $1.6M |
| palo alto investors lp | 1,010,510 | $1.5M |
| 683 capital management, llc | 896,263 | $1.3M |
| renaissance technologies llc | 888,680 | $1.3M |
| blackrock, inc. | 788,839 | $1.2M |
| geode capital management, llc | 598,121 | $874K |
| jacobs levy equity management, inc | 460,997 | $673K |
| millennium management llc | 397,625 | $581K |
Showing top 10 of 74 institutional holders of Pyxis Oncology, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 5.1%
- Days to cover
- 7.7
- Shares short
- 2,660,931
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PYXS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Pyxis Oncology, Inc.?
Pyxis Oncology, Inc. is a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) targeting solid tumors, with its lead candidate micvotabart pelidotin (formerly PYX-201) in Phase 1/2 trials. The company has no approved products, has not generated product revenue, and has incurred significant operating losses since inception.
What is Pyxis Oncology, Inc.'s lead drug candidate?
Pyxis Oncology, Inc.'s most advanced tracked candidate is micvotabart pelidotin (Phase 1/Phase 2) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Who is the CEO of Pyxis Oncology, Inc.?
Mr. Thomas Civik is the chief executive officer of Pyxis Oncology, Inc. (PYXS).
Where is Pyxis Oncology, Inc. headquartered?
Pyxis Oncology, Inc. (PYXS) is headquartered in Boston, MA, United States.
What therapeutic areas does Pyxis Oncology, Inc. focus on?
Pyxis Oncology, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.